



<b>Name of Sponsor/Company:</b> Mutual Pharmaceutical Co., Inc. 1100 Orthodox Street Philadelphia, PA 19124	<b>Page 2 of 2</b>	<b>Mutual Pharmaceutical Company, Inc</b> <i>This report is the property of Mutual Pharmaceutical Company, Inc, and may not be used without the permission of Mutual Pharmaceutical Co., Inc.</i>
<b>Name of Finished Product:</b> Zonisamide Capsules, 100mg	<b>Report Date:</b> March 2005	
<b>Name of Active Ingredient:</b> Zonisamide	<b>Final Report Number:</b> R04-1376	

**Criteria for evaluation:** Bioequivalence

**SUMMARY – CONCLUSIONS**

**Bioequivalence:** Mutual Pharmaceutical’s Zonisamide Capsules, 100mg were bioequivalent to Elan Biopharmaceutical’s Zonegran® Capsules, 100mg with respect to C<sub>max</sub>, AUC<sub>0-72</sub> when administered under fasting conditions. The results are summarized in the table below:

<b>Zonisamide</b>	<b>Ln-Transformed C<sub>max</sub></b>	<b>Ln Transformed AUC<sub>0-72</sub></b>
Test Product Geometric	1005.78	41053.73
Reference Product Geometric Mean	1016.10	41417.81
% Ratio	98.98	99.12
90% Confidence Interval	(94.02, 104.21)	(96.87, 101.43)